Overview
- Editors:
-
-
W. Evan Secor
-
Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, USA
-
Daniel G. Colley
-
Center for Tropical and Emerging Global Diseases and Department of Microbiology, University of Georgia, USA
- Provides insights into the research and programs currently related to schistosomiasis, and uses these insights to project into future years of work on schistosomiasis, from research to public health interventions
- The intent is to lead to constructive efforts to identify and address the most critical questions and challenges related to schistosomiasis
- Includes supplementary material: sn.pub/extras
Access this book
Other ways to access
Table of contents (15 chapters)
-
-
- Eric S. Loker, Gerald M. Mkoji
Pages 1-11
-
- Paul J. Brindley, Claudia S. Copeland, Bernd H. Kalinna
Pages 13-26
-
- Philip T. LoVerde, Edward G. Niles, Ahmed Osman, Wenjie Wu
Pages 27-43
-
- David L. Williams, Raymond J. Pierce
Pages 45-64
-
- Adrian P. Mountford, Stephen J. Jenkins
Pages 65-79
-
-
- Karl F. Hoffmann, Jennifer M. Fitzpatrick
Pages 101-112
-
-
- Thomas Wynn A., Allen Cheever W., Mallika Kaviratne, Robert Thompson W., Margaret Mentink-Kane M., Matthias Hesse
Pages 125-140
-
- David W. Dunne, Mark Booth
Pages 141-158
-
- Donald P. McManus, Zheng Feng, Jiagang Guo, Yuesheng Li, Paul B. Bartley, Alex Loukas et al.
Pages 159-175
-
- Jeffrey M. Bethony, Jeff T. Williams
Pages 177-190
-
- Donato Cioli, Livia Pica-Mattoccia
Pages 191-206
-
- Dirk Engels, Lorenzo Savioli
Pages 207-222
-
-
Back Matter
Pages 233-235
About this book
Human schistosomiasis is a disease with a rich and well-documented past, and every expectation of an unfortunately long future. These infections were known to the ancient Egyptians and their transmission shows little evidence of slowing down, globally. The good news is that field applicable, and increasingly affordable, chemotherapy has been available for almost 25 years. Using chemotherapy and other means of control, some countries have decreased transmission and made excellent headway against morbidity. The bad news is that the public health problems caused by schistosomiasis are still with us, with the estimated number of cases of schistosomiasis, while shifting geographically, remaining approximately 200 million for the last 30 years. In fact, with the development of field usable ultrasound technology and meta-analyses performed on existing data, there is a new appreciation for the extent of non-lethal morbidity associated with these infections. While the percentage of individuals with severe hepatosplenic disease remains below 10%, recent reassessments of morbidity associated with schistosomiasis indicate that the prevelance of symptoms and the cost in diability-adjusted life years is much greater than was previously, commonly appreciated (Van der Werf, M. J. , et al. 2003, Acta Tropica 86:125-139; Charles H. King, personnel communication). Strong impetus for addressing these issues is provided by the World Health Assembly’s recently passed Resolution 54. 19, which calls for efforts to reduce morbidity caused by schistosomiasis and soil-transmitted helminths in school-aged children, largely through chemotherapy campaigns.
Editors and Affiliations
-
Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, USA
W. Evan Secor
-
Center for Tropical and Emerging Global Diseases and Department of Microbiology, University of Georgia, USA
Daniel G. Colley
